As the world's largest protein producer, JBS N.V. (JBS) manages a diversified portfolio that includes beef, pork, poultry, and processed foods across North America, Brazil, Australia, and Europe. After delivering record full-year 2025 revenue of $86 billion and net income of $2 billion, the upcoming Q1 2026 earnings report will provide insight into whether that momentum continues, particularly with tight U.S. cattle supplies and shifting global demand. From my perspective, this report is crucial for investors because it sheds light on operational efficiency, segment performance, and capital allocation decisions in a challenging commodity market. With shares trading near recent highs following the NYSE listing, the results could indicate if JBS can sustain its advantage across multiple proteins amid inflation and supply chain issues, which would also have implications for peers like Pilgrim's Pride.
Analysts are forecasting consensus revenue of $21.68 billion for Q1 2026 (January-March), a slight increase from prior periods, supported by volume growth in poultry and prepared foods that should offset headwinds in beef. The EPS consensus comes in at $0.24, with estimates ranging from $0.20 to $0.32—this follows Q4 2025's reported $0.39 against an expected $0.41. Key figures to watch include adjusted EBITDA, with margins projected around 7-8% in line with full-year trends, and leverage moving toward 2.5x or lower.
Looking back, the company has consistently beaten revenue expectations: Q4 2025 came in at $23.06 billion versus $22.6 billion anticipated (+15% YoY), and Q3 hit $22.6 billion (also a beat). EPS results have been more varied, with Q4 slightly missing the mark but full-year EPS rising 15% to $1.89. Stock reactions have been muted post-Q4 despite the revenue strength. I expect guidance to cover 2026 capex of $2.4 billion (split between expansion and maintenance) along with working capital requirements.
Investor sentiment heading into Q1 earnings feels cautiously optimistic. Recent analyst upgrades, such as Goldman Sachs' 'Buy' rating with a $48 price target, have pushed shares to 7-month highs. The overall consensus remains a Strong Buy, supported by the strong 2025 performance. That said, risks persist from tight U.S. beef supplies and elevated grain costs. Historically, beats have led to 5-10% upside, while misses could add pressure in this volatile environment. One thing that stands out to me is how resilient the stock has been amid these upgrades.
In reviewing JBS, I also checked this using Tickeron’s AI Screener, which helps me filter stocks and ETFs based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. It scans thousands of instruments with customizable filters like industry, market cap, technical indicators, price patterns, and performance metrics, making it easier to spot trade ideas, trending stocks, breakout candidates, and opportunities that might otherwise take hours to uncover manually. I find it particularly useful for comparing companies like JBS against sector peers efficiently.
Once earnings are out, attention will turn to reaffirmation of 2026 guidance. Management aims for EBITDA cash flow breakeven at $5.7 billion, factoring in $2.4 billion in capex and stable working capital—this should support free cash flow after 2025's $400 million generation.
Segment performance deserves close monitoring: Beef in North America continues to face cattle supply constraints into 2026, though exports from Australia and Brazil provide some balance. Upside potential lies in poultry (Pilgrim's Pride, Seara) and U.S. pork expansions, including new Iowa plants ramping up by 2027 to add $500-750 million in revenue at double-digit margins. Prepared foods have shown resilience with growth exceeding 25% in recent quarters.
Broader macro influences include commodity prices for grains and livestock, currency fluctuations (BRL/USD), and demand trends in China and the EU following reopenings. Leverage stood at 2.39x at Q4's end, providing room for buybacks and dividends ($1/share ex-May 18), with $7.4 billion in liquidity enabling opportunistic M&A. I'm watching Q2 trends closely as they will shape the full-year path toward revenue exceeding $88 billion.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
JBS moved above its 50-day moving average on July 24, 2026 date and that indicates a change from a downward trend to an upward trend. In of 51 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 52 cases where JBS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The 10-day moving average for JBS crossed bullishly above the 50-day moving average on July 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where JBS advanced for three days, in of 283 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 234 cases where JBS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for JBS moved out of overbought territory on August 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on August 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on JBS as a result. In of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for JBS turned negative on August 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JBS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
JBS broke above its upper Bollinger Band on July 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.528) is normal, around the industry mean (8.481). P/E Ratio (12.916) is within average values for comparable stocks, (36.558). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.944). Dividend Yield (0.072) settles around the average of (0.055) among similar stocks. P/S Ratio (0.160) is also within normal values, averaging (5.907).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. JBS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock slightly better than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows